F. Wielaard

491 total citations
16 papers, 390 citations indexed

About

F. Wielaard is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and Pharmacy. According to data from OpenAlex, F. Wielaard has authored 16 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 5 papers in Public Health, Environmental and Occupational Health and 4 papers in Pharmacy. Recurrent topics in F. Wielaard's work include Cytomegalovirus and herpesvirus research (5 papers), Diabetes Management and Education (4 papers) and Obesity and Health Practices (4 papers). F. Wielaard is often cited by papers focused on Cytomegalovirus and herpesvirus research (5 papers), Diabetes Management and Education (4 papers) and Obesity and Health Practices (4 papers). F. Wielaard collaborates with scholars based in Netherlands, United States and Belgium. F. Wielaard's co-authors include W. Duermeyer, J. Van Der Veen, P. Vermunt, Gert P. Westert, I.E.J. Milder, Hans van Oers, J.H.M. de Vries, Caroline A. Baan, Caroline Baan and A Joss and has published in prestigious journals such as Diabetes Care, Journal of Clinical Microbiology and Diabetic Medicine.

In The Last Decade

F. Wielaard

15 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Wielaard Netherlands	10	164	95	87	70	56	16	390
Sérgio Setúbal Brazil	14	108 0.7×	26 0.3×	79 0.9×	315 4.5×	6 0.1×	45	570
Sigal Yawetz United States	14	234 1.4×	26 0.3×	131 1.5×	340 4.9×		26	656
B McLaughlin Canada	11	197 1.2×	5 0.1×	62 0.7×	223 3.2×	4 0.1×	27	444
Elizabeth Brown United States	10	100 0.6×	21 0.2×	64 0.7×	53 0.8×		16	291
Jussara Silveira Brazil	14	149 0.9×	13 0.1×	35 0.4×	522 7.5×	9 0.2×	32	641
JJ Eron United States	8	108 0.7×	3 0.0×	68 0.8×	190 2.7×	45 0.8×	9	398
L Izaley Democratic Republic of the Congo	7	214 1.3×	5 0.1×	37 0.4×	176 2.5×	6 0.1×	9	358
Susan Morrison United States	10	202 1.2×	86 0.9×	34 0.4×	191 2.7×	1 0.0×	16	527
AntheaJ. Tilzey United Kingdom	13	241 1.5×	14 0.1×	76 0.9×	149 2.1×	4 0.1×	21	443
Faouzi Souala France	10	206 1.3×	5 0.1×	64 0.7×	240 3.4×	8 0.1×	19	424

Countries citing papers authored by F. Wielaard

Since Specialization

Citations

This map shows the geographic impact of F. Wielaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Wielaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Wielaard more than expected).

Fields of papers citing papers by F. Wielaard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Wielaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Wielaard. The network helps show where F. Wielaard may publish in the future.

Co-authorship network of co-authors of F. Wielaard

This figure shows the co-authorship network connecting the top 25 collaborators of F. Wielaard. A scholar is included among the top collaborators of F. Wielaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Wielaard. F. Wielaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Vermunt, P., I.E.J. Milder, F. Wielaard, et al.. (2013). Behavior change in a lifestyle intervention for type 2 diabetes prevention in Dutch primary care: opportunities for intervention content. BMC Family Practice. 14(1). 78–78. 21 indexed citations

Vermunt, P., I.E.J. Milder, F. Wielaard, et al.. (2012). A lifestyle intervention to reduce Type 2 diabetes risk in Dutch primary care: 2.5‐year results of a randomized controlled trial. Diabetic Medicine. 29(8). e223–31. 42 indexed citations

Vermunt, P., I.E.J. Milder, F. Wielaard, et al.. (2012). Implementation of a lifestyle intervention for type 2 diabetes prevention in Dutch primary care: opportunities for intervention delivery. BMC Family Practice. 13(1). 79–79. 33 indexed citations

Vermunt, P., I.E.J. Milder, F. Wielaard, et al.. (2011). Lifestyle Counseling for Type 2 Diabetes Risk Reduction in Dutch Primary Care. Diabetes Care. 34(9). 1919–1925. 46 indexed citations

Vermunt, P., I.E.J. Milder, F. Wielaard, Hans van Oers, & Gert P. Westert. (2010). An active strategy to identify individuals eligible for type 2 diabetes prevention by lifestyle intervention in Dutch primary care: the APHRODITE study. Family Practice. 27(3). 312–319. 20 indexed citations

Ho-Terry, Linda, et al.. (1988). Diagnosis of fetal rubella infection by nucleic acid hybridization. Journal of Medical Virology. 24(2). 175–182. 19 indexed citations

Wielaard, F., et al.. (1988). Development of an antibody-capture IgM-enzyme-linked immunosorbent assay for diagnosis of acute epstein-barr virus infections. Journal of Virological Methods. 21(1-4). 105–115. 9 indexed citations

Wielaard, F., et al.. (1987). A sol-particle immunoassay for determination of anti-rubella antibodies; development and clinical validation. Journal of Virological Methods. 17(1-2). 149–158. 9 indexed citations

Wielaard, F., et al.. (1987). A one-step enzyme-linked immunosorbent assay to detect anti-CMV antibodies; development and clinical validation. Journal of Virological Methods. 17(1-2). 141–148.

10.

Wielaard, F., et al.. (1986). Development of CMV Antibody Tests and Their Clinical Evaluation. Vox Sanguinis. 51(s1). 31–34. 4 indexed citations

11.

Wielaard, F., et al.. (1985). Development and preliminary evaluation of two ELISAs for detection of anti-CMV Ig and IgM antibodies. Journal of Virological Methods. 10(4). 363–369. 6 indexed citations

12.

Wielaard, F., et al.. (1985). Clinical validation of an antibody-capture anti-rubella IgM-ELISA. Journal of Virological Methods. 10(4). 349–354. 7 indexed citations

13.

Wielaard, F., et al.. (1983). Diagnosis of acute toxoplasmosis by an enzyme immunoassay for specific immunoglobulin m antibodies. Journal of Clinical Microbiology. 17(6). 981–987. 32 indexed citations

14.

Duermeyer, W., et al.. (1980). Enzyme-Linked Immunosorbent Assay for Detection of Immunoglobulin M Antibodies Against Toxoplasma gondii. Journal of Clinical Microbiology. 12(6). 805–806. 16 indexed citations

15.

Helmsing, P.J., et al.. (1980). An outbreak of hepatitis a in an institution for the mentally retarded. Journal of Medical Virology. 5(2). 143–150. 7 indexed citations

16.

Duermeyer, W., F. Wielaard, & J. Van Der Veen. (1979). A new principle for the detection of specific IgM antibodies applied in an ELISA for hepatitis a. Journal of Medical Virology. 4(1). 25–32. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact